The anti-obesity drug industry was in 2023 valued at $5.6 billion and will exhibit a CAGR of 27% between 2024 and 2032 (expert opinion).
$LLY+1.1%, $NVO+2.1% and others are creating drugs like - Ozempic, Wegovy, Mounjaro and Zepbound - These are blockbusters in terms of weight loss market in my opinion. But which companies may have the best chance to take the biggest bite of that imaginary pie of such a huge market? Does anyone have a breakdown of who is doing the best, having success, or just having promising results?
I'd like to give some of these companies a chance, so I'd be happy for opinions. After all, obesity is a big topic and probably will be for a long time.
For me ro are both great companies. I wouldn't be afraid to include them in my portfolio. At what price would you buy $LLY+1.1%?
It's interesting, but this growth is probably not very sustainable. The stock is overpriced and I definitely don't want to buy their stock.
Both stocks pretty expensive. Depends on what angle I'm looking at. On the one hand, it looks expensive from a % (chart) perspective. On the other hand, given that the sector will continue to thrive and companies will continue to grow, it's not that expensive.
I don't see it as super overpriced, but it is expensive so I'm not buying and waiting for some downside.
Both stocks are pretty high, but their industry is just going to be here to stay and make more money. More people are retiring, so they are living to a higher age and drugs are needed in greater quantities. It's a good business. Do you have any of these two companies in your portfolio?